Answers are grounded in this paper and cite their sources.
Background Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder for which a variety of disease-modifying therapies (DMTs) with distinct mechanisms of action are now available. However, interindividual variability in drug response remains a significant clinical challenge. Objectives This narrative review aims to provide a comprehensive synthesis of the current evidence on pharmacogenetic markers associated with MS treatment response and toxicity, incorporating recent pharmacogenomic literature. Methods Based on data from the ClinPGx curated database and recent pharmacogenomic literature, pharmacogenetic variants associated with altered drug response were identified and categorized by phenotype and level of evidence. Results CYP2C9 haplotypes represent the only pharmacogenetic marker with regulatory actionability, guiding siponimod dosing. Recent larger studies identified MAP3K1 (rs2053696) as a genome-wide significant predictor of glatiramer acetate response, and HLA-A*03:01 as a clinically relevant marker enabling personalized choice between glatiramer acetate and interferon-β. For interferon-β, HLA haplotypes predict formulation-specific immunogenicity with high accuracy, while SLC9A9 represents a validated efficacy predictor. For anti-CD20 therapies, FCGR3A V158F (rs396991) is emerging as a class-level pharmacogenetic determinant of B-cell depletion. Conclusions Pharmacogenetics holds real promise for personalizing DMT selection in MS. Future integration of pharmacogenetic testing into clinical practice, supported by larger and more diverse cohorts, could support more effective and safer treatment strategies for individuals with MS.
No takes yet. Share an insight, caveat, or question.
Floris et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: